RINVOQ is the first and only oral Janus kinase (JAK) inhibitor approved in the European Union (EU) to treat adult patients with giant cell arteritis (GCA) The approval ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback